Check patentability & draft patents in minutes with Patsnap Eureka AI!

Use of extract of Phyllanthus emblica L. for the preparation of pharmaceutical composition for enhancing mitochondrial activity in patient with MERRF syndrome

A pharmaceutical composition, the technology of emblica, applied in the direction of drug combination, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve the lack of mitochondrial energy to meet cell growth and metabolism, mitochondrial respiratory chain complex enzyme function defects, etc. question

Pending Publication Date: 2018-12-04
TAIWAN MITOCHONDRION APPLIED TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

About 80% of patients with MERRF syndrome are due to mitochondrial DNA tRNA Lys A8344G point mutation occurs in the gene, which makes the enzyme function of the mitochondrial respiratory chain complex in the cells of patients with MERRF syndrome severely defective, resulting in insufficient energy produced by the mitochondria to meet the needs of cell growth and metabolism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of extract of Phyllanthus emblica L. for the preparation of pharmaceutical composition for enhancing mitochondrial activity in patient with MERRF syndrome
  • Use of extract of Phyllanthus emblica L. for the preparation of pharmaceutical composition for enhancing mitochondrial activity in patient with MERRF syndrome
  • Use of extract of Phyllanthus emblica L. for the preparation of pharmaceutical composition for enhancing mitochondrial activity in patient with MERRF syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The experimental parameters and experimental measurement results of embodiment one, embodiment two, comparative example one and comparative example two are as follows Figure 3 to Figure 9 shown. image 3 It is a schematic diagram of the oxygen consumption of mitochondrial synthesis of ATP in Example 1 and Comparative Example 1 of the present invention. Figure 4 It is a schematic diagram of the basal oxygen consumption of mitochondria in Example 1 and Comparative Example 1 of the present invention. Figure 5 It is a schematic diagram of the maximum oxygen consumption capacity of mitochondria in Example 1 and Comparative Example 1 of the present invention. Figure 6 It is a schematic diagram of the pre-stored oxygen consumption capacity of mitochondria in Example 1 and Comparative Example 1 of the present invention. Figure 7 It is a schematic diagram of oxygen consumption for mitochondrial synthesis of ATP in Example 2 and Comparative Example 2 of the present inventi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of the extract of Phyllanthus emblica L. for the preparation of a pharmaceutical composition for enhancing mitochondrial activity in a patient with MERRF syndrome comprises providing a Phyllanthus emblica extract. When a pharmaceutical composition comprising a Phyllanthus emblica extract is supplied to cells of a patient of MERRF syndrome, the Phyllanthus emblica extract enhances the ability of a plurality of mitochondria in the cells of the MERRF syndrome patient to undergo oxidative phosphorylation reaction and adenosine triphosphate (ATP) synthesis.

Description

technical field [0001] The invention relates to the preparation of a pharmaceutical composition for improving the mitochondrial activity of patients with myoclonic epilepsy with Ragged Red Fibers (Myoclonic Epilepsy with Ragged Red Fibers, MERRF). Use of a pharmaceutical composition for mitochondrial activity. Background technique [0002] Mitochondria is the main site for oxidative phosphorylation and synthesis of adenosine triphosphate (ATP) in cells. Since adenosine triphosphate is the energy source for cell activities, mitochondria are also known as "cell energy factories". In addition to providing energy for cells, mitochondria are also involved in processes such as cell differentiation, cell information transmission, and cell apoptosis, and have the ability to regulate cell growth cycles. [0003] However, in patients with mitochondrial disease, the diseased mitochondria are not active enough to cause problems in the patient's cells. For example, MERRF syndrome (Myo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/47A61P3/00
CPCA61K36/47A61P3/00
Inventor 郑汉中凃启堂杨舜傑
Owner TAIWAN MITOCHONDRION APPLIED TECH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com